Tzikas Apostolos, Mylotte Darren, Bergmann Martin
AHEPA University Hospital, Thessaloniki, Greece.
Galway University Hospital, Galway, Ireland.
Interv Cardiol. 2015 May;10(2):109-111. doi: 10.15420/icr.2015.10.2.109.
Percutaneous left atrial appendage occlusion (LAAO) is a device-based therapy for the prevention of stroke in patients with non-valvular atrial fibrillation (AF). Recently, the Watchman device (Boston Scientific, St Paul, MN, US) was approved in the US by the Food and Drug Administration (FDA) based on the results of two randomised clinical trials that evaluated LAAO in patients eligible for oral anticoagulation (OAC) therapy. However, in real-word clinical practice LAAO is typically offered to patients ineligible for OAC therapy, as they appear to have limited treatment options and consequently worse prognosis. Although LAAO has shown favourable clinical outcomes in OAC-ineligible patients in single or multicentre observational studies, these results need to be confirmed in randomised clinical trials.
经皮左心耳封堵术（LAAO）是一种用于预防非瓣膜性心房颤动（AF）患者中风的基于器械的治疗方法。最近，基于两项评估LAAO用于适合口服抗凝药（OAC）治疗患者的随机临床试验结果，美国食品药品监督管理局（FDA）批准了Watchman装置（美国明尼苏达州圣保罗市波士顿科学公司）。然而，在实际临床实践中，LAAO通常用于不适合OAC治疗的患者，因为这些患者似乎治疗选择有限，因此预后较差。尽管在单中心或多中心观察性研究中，LAAO在不适合OAC治疗的患者中已显示出良好的临床结果，但这些结果需要在随机临床试验中得到证实。
